Tower Research Capital (TRC)’s Petros Pharmaceuticals PTPI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Hold |
0
| – | -$1 | – | 5513 |
|
|
2025
Q1 | – | Hold |
0
| – | – | – | 5123 |
|
|
2024
Q4 | – | Sell |
-130
| Closed | -$1.16K | – | 5937 |
|
|
2024
Q3 | $1.16K | Sell |
130
-1
| -0.8% | -$9 | ﹤0.01% | 5195 |
|
|
2024
Q2 | $1.5K | Sell |
131
-5
| -4% | -$80 | ﹤0.01% | 5150 |
|
|
2024
Q1 | $5.03K | Sell |
136
-229
| -63% | -$8.07K | ﹤0.01% | 4594 |
|
|
2023
Q4 | $12.9K | Buy |
365
+263
| +258% | +$9.41K | ﹤0.01% | 4009 |
|
|
2023
Q3 | $4.4K | Hold |
102
| – | – | ﹤0.01% | 4871 |
|
|
2023
Q2 | $5.17K | Buy |
102
+10
| +11% | +$779 | ﹤0.01% | 4854 |
|
|
2023
Q1 | $3K | Buy |
92
+72
| +360% | +$4.1K | ﹤0.01% | 5231 |
|
|
2022
Q4 | $1K | Buy |
+20
| New | +$1.93K | ﹤0.01% | 5650 |
|
|
2022
Q2 | – | Sell |
-16
| Closed | -$6K | – | 6437 |
|
|
2022
Q1 | $6K | Buy |
16
+3
| +23% | +$1.26K | ﹤0.01% | 4914 |
|
|
2021
Q4 | $11K | Buy |
+13
| New | +$7.62K | ﹤0.01% | 4443 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 6081 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 5762 |
|
Tower Research Capital (TRC)'s PTPI Position: Q2 2025 in Review
Tower Research Capital (TRC) held its Petros Pharmaceuticals (PTPI) position steady in Q2 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5513.
Tower Research Capital (TRC) first reported a position in PTPI in Q4 2021 and has held it in 10 quarters since. The position peaked at $12.9K in Q4 2023. 0 funds tracked by Wall St. Rank hold PTPI as of Q2 2025.
- Tower Research Capital (TRC) held 0 shares of Petros Pharmaceuticals worth $0 as of Q2 2025.
- Tower Research Capital (TRC) left its Petros Pharmaceuticals share count unchanged in Q2 2025.
- Petros Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2025, its #5513 holding.
- Tower Research Capital (TRC) first reported a position in Petros Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
- Tower Research Capital (TRC)'s Petros Pharmaceuticals position peaked at $12.9K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.